Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

USP7 inhibitor P5091 enhances the antitumor efficacy of vemurafenib in BRAFV600E-mutant thyroid cancer via ferroptosis.

Biochemical pharmacology - 1 Jan 2026

Hu Chenchen, Tian Wenzhi, Tang Yun, Wang Peiran, Kuan Tiantian, Wei Wei, Chen Dong, Li Peng, Su Xi

Abstract excerpt

Resistance to the BRAF inhibitor vemurafenib (PLX4032) limits its efficacy in thyroid cancer. Ubiquitin-specific peptidase 7 (USP7), a key regulator of oncogenic signaling, and USP7 inhibitor may help overcome drug resistance. This study investigated the combined efficacy of PLX4032 and the USP7 inhibitor P5091 in BRAFV600E-mutant thyroid cancer. Bioinformatics showed that USP7 and integrin subunit beta 3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Drug Synergism

Share to Ferroptosis

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Neoplasms

Share to Vemurafenib

Source

Identifiers

PMID: 41207567
DOI: 10.1016/j.bcp.2025.117522

Genes

USP7
BRAF
GPX4
ITGB3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

USP7 inhibitor P5091 enhances the antitumor efficacy of vemurafenib in BRAFV600E-mutant thyroid cancer via ferroptosis.PMID 41207567Read ↗

MitoCur‐1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14Semantic proximity Read ↗

Role of Annexin 7 (ANXA7) as a tumor suppressor and a regulator of drug resistance in thyroid cancerSemantic proximity Read ↗

USP8 positively regulates hepatocellular carcinoma tumorigenesis and confers ferroptosis resistance through β-catenin stabilizationSemantic proximity Read ↗

Role of Annexin 7 (ANXA7) as a Tumor Suppressor and a Regulator of Drug Resistance in Thyroid Cancer.Semantic proximity Read ↗

BRAF-activated ARSI suppressed EREG-mediated ferroptosis to promote BRAFV600E (mutant) papillary thyroid carcinoma progression and sorafenib resistance.Semantic proximity Read ↗

Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.Semantic proximity Read ↗

Parthenolide leads to proteomic differences in thyroid cancer cells and promotes apoptosisSemantic proximity Read ↗

The deubiquitinase USP24 suppresses ferroptosis in triple-negative breast cancer by stabilizing DHODH proteinSemantic proximity Read ↗

Identification of mechanism of the oncogenic role of FGFR1 in papillary thyroid carcinomaSemantic proximity Read ↗

Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.Semantic proximity Read ↗

Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib.Semantic proximity Read ↗

Investigating USP42 Mutation as Underlying Cause of Familial Non-Medullary Thyroid Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.